Pharmaceuticals, Biotechnology & Life Sciences

VG Life Sciences Inc. pioneers breakthrough therapies for cancer, infections and autoimmune diseases—small cap, big impact on patient care and biotech innovation.

Recordati faces a €10.9 bn takeover bid from CVC Capital, sparking a market sell‑off and raising questions on valuation, debt, and future R&D synergies.

Milestone Pharmaceuticals’ upcoming presentation at the Needham Virtual Healthcare Conference highlights its CARDAMYST® nasal spray and innovative cardiovascular pipeline, offering investors fresh insight into the company’s growth potential and mark…

Onco‑Innovations expands in Australia, partnering with RDI Partners and forming a local subsidiary to fast‑track Phase I oncology trials while leveraging 43.5% R&D tax credits.

Galmed Pharmaceuticals, a biopharma innovator, develops liver disease and gallstone treatments, shares trade on Nasdaq, and aims to improve patient outcomes.

Discover how Zymeworks’ CFO Kristin Stafford’s new stock options and restricted‑stock grants reshape executive ownership and signal strategic shifts in its cancer‑biotherapeutic pipeline.

Galderma’s new Sculptra & Restylane trials show lasting volume boost for menopausal & weight‑loss patients, while its ALASTIN Signature Practice rollout aims to elevate peri‑procedural care in the US.

Beleave Inc. faces steep financial volatility in Canada’s cannabis sector, while Bloom Energy’s solid‑oxide fuel cell tech earns top trust on Newsweek’s 2026 list.

Moderna’s April 8 bullish momentum and upcoming ESCMID data on its mRNA‑1010 influenza vaccine promise to drive pipeline expansion, regulatory gains, and stock upside.

Abionyx Pharma SA is pioneering novel therapies for renal and eye diseases, with flagship candidates CER‑001, CER‑002, and CER‑209 targeting heart, metabolic, and liver disorders.